We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | NASDAQ:IOVA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.81 | 6.29% | 13.69 | 11.50 | 26.00 | 13.8799 | 13.30 | 13.46 | 4,292,824 | 05:00:12 |
|
Delaware
|
| |
75-3254381
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(I.R.S. Employer
Identification Number) |
|
|
Large accelerated filer
☒
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☐ (Do not check if a smaller reporting company)
|
| |
Smaller reporting company
☐
|
|
| | | |
Emerging growth company
☐
|
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | |
|
Securities and Exchange Commission registration fee
|
| | |
|
(1)
|
| |
|
FINRA filing fee
|
| | |
|
(1)
|
| |
|
Printing and engraving expenses
|
| | |
|
(2)
|
| |
|
The Nasdaq Global Market listing fees
|
| | |
|
(2)
|
| |
|
Legal fees and expenses
|
| | |
|
(2)
|
| |
|
Accounting fees and expenses
|
| | |
|
(2)
|
| |
|
Transfer agent and registrar fees
|
| | |
|
(2)
|
| |
|
Miscellaneous expenses
|
| | |
|
(2)
|
| |
|
Total
|
| | | $ | (2) | | |
| IOVANCE BIOTHERAPEUTICS, INC. | | | | | |||
| By: | | | /s/ Maria Fardis | | | ||
| | | | Maria Fardis, Ph.D., M.B.A. | | | ||
| | | | President and Chief Executive Officer | | |
|
Signature
|
| |
Title
|
|
|
/s/ Maria Fardis, Ph.D., M.B.A.
Maria Fardis, Ph.D., M.B.A.
|
| |
President and Chief Executive Officer and Director
(Principal Executive Officer) |
|
|
/s/ Timothy E. Morris
Timothy E. Morris
|
| |
Chief Financial Officer
(Principal Financial and Accounting Officer) |
|
|
/s/ Athena Countouriotis, M.D.
Athena Countouriotis, M.D.
|
| |
Director
|
|
|
/s/ Iain Dukes, D. Phil.
Iain Dukes, D. Phil.
|
| |
Director
|
|
|
/s/ Ryan Maynard
Ryan Maynard
|
| |
Director
|
|
|
/s/ Merrill A. McPeak
Merrill A. McPeak
|
| |
Director
|
|
|
/s/ Wayne Rothbaum
Wayne Rothbaum
|
| |
Director
|
|
|
/s/ Michael Weiser, M.D., Ph.D.
Michael Weiser, M.D., Ph.D.
|
| |
Director
|
|
1 Year Iovance Biotherapeutics Chart |
1 Month Iovance Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions